Clinical trials referenced in this document:
Documents that mention this clinical trial
Nine contemporary therapeutic directions in heart failure
New drugs in preclinical and early stage clinical development in the treatment of heart failure
Heart failure with preserved ejection fraction: controversies, challenges and future directions
Mapping Progress in Reducing Cardiovascular Risk with Kidney Disease
Effects of sacubitril/valsartan on glycemia in patients with diabetes and heart failure: the PARAGON-HF and PARADIGM-HF trials
Sacubitril/valsartan: beyond natriuretic peptides
Funding for this research was provided by:
Swedish Heart Association
Swedish Society of Medicine
National Heart, Lung and Blood Institute postdoctoral training grant (T32HL094301)
National Institutes of Health (R01 HL107577, R01 HL127028, R01 HL140731, R01 HL149423)
British Heart Foundation Centre of Research Excellence Grant (RE/18/6/34217)
Received: 11 April 2022
Accepted: 5 June 2022
First Online: 18 June 2022
: The study was approved by the appropriate national and institutional regulatory and ethics boards and all patients provided written informed consent.
: Not applicable.
: MOW has served on advisory boards or lectured for MSD, Lilly, Novo Nordisk and Sanofi, and has organized a professional regional meeting sponsored by Lilly, Rubin Medical, Sanofi, Novartis and Novo Nordisk. BC reports consulting for Amgen, Boehringer Ingelheim, Corvia, Myokardia, Novartis. MV has received research grant support or served on advisory boards for American Regent, Amgen, AstraZeneca, Bayer AG, Baxter Healthcare, Boehringer Ingelheim, Cytokinetics, Lexicon Pharmaceuticals, Relypsa, and Roche Diagnostics, speaker engagements with Novartis and Roche Diagnostics, and participates on clinical endpoint committees for studies sponsored by Galmed and Novartis. MP reports the following disclosures: Abbvie, Actavis, Amgen, Amarin, AstraZeneca, Boehringer Ingelheim, Bristol Myers Squibb, Casana, CSL Behring, Cytokinetics, Johnson & Johnson, Lilly, Moderna, Novartis, ParatusRx, Pfizer, Relypsa, Salamandra, Synthetic Biologics, Theravance. MZ reports consulting for Novartis, and is a member of the steering committees for both PARADIGM-HF and PARAGON-HF. JR reports the following disclosures: Consultant Novartis, Aventis, AstraZeneca, Bayer, Myokardia/BMS. KS reports honoraria from Astrazeneca, Boerhinger-Mannheim, Novartis. ML is a full-time employee of Novartis Pharmaceuticals. SJS has received research grants from Actelion, AstraZeneca, Corvia, Novartis, and Pfizer; and has served consulting fees from Abbott, Actelion, AstraZeneca, Amgen, Axon Therapeutics, Bayer, Boehringer-Ingelheim, Bristol-Myers Squibb, Cardiora, CVRx, Cytokinetics, Edwards, Eisai, Ionis, Ironwood, Merck, MyoKardia, Novartis, Prothena, Pfizer, Regeneron, Sanofi, Shifamed, Tenax, and United Therapeutics. MAP reports research grant support to institution from Novartis; serves on PARAGON-HF Steering Committee and Study Chair of PARADISE-MI; reports consulting for AstraZeneca, Boehringer Ingelheim and Eli Lilly Alliance, Corvidia, DalCor, GlaxoSmithKline, NHLBI CONNECTs (Master Protocol Committee), Novartis, Novo Nordisk, Peerbridge and Sanofi; and has equity in DalCor and Peerbridge. JJVM reports payments to his employer, Glasgow University, for his work on clinical trials, consulting and other activities: Alnylam, Amgen, AstraZeneca, Bayer, Boehringer Ingelheim, BMS, Cardurion, Cytokinetics, Dal-Cor, GSK, Ionis, KBP Biosciences, Novartis, Pfizer, Theracos, and personal payments: Abbott, Alkem Metabolics, Eris Lifesciences, Hikma, Ionis, Lupin, ProAdWise Communications, Sun Pharmaceuticals, Servier. SDS has received research grants from Actelion, Alnylam, Amgen, AstraZeneca, Bellerophon, Bayer, BMS, Celladon, Cytokinetics, Eidos, Gilead, GSK, Ionis, Lilly, Mesoblast, MyoKardia, NIH/NHLBI, Neurotronik, Novartis, NovoNordisk, Respicardia, Sanofi Pasteur, Theracos, and has consulted for Abbott, Action, Akros, Alnylam, Amgen, Arena, AstraZeneca, Bayer, Boeringer-Ingelheim, BMS, Cardior, Cardurion, Corvia, Cytokinetics, Daiichi-Sankyo, GSK, Lilly, Merck, Myokardia, Novartis, Roche, Theracos, Quantum Genomics, Cardurion, Janssen, Cardiac Dimensions, Tenaya, Sanofi-Pasteur, Dinaqor, Tremeau, CellProThera, Moderna, American Regent, Sarepta. JCW, RR and AJ report no disclosures.